Abstract:Aims To assess the impact of long-term visit-to-visit variability in HbA 1c on microvascular outcomes in type 2 diabetes mellitus (T2DM), and its influence on the effects of intensive glycemic control. Methods Included were participants with T2DM enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) who had at least three measurements of HbA 1c prior to new-onset microvascular outcomes, namely nephropathy, retinopathy and neuropathy. Variability in HbA 1c was defined as the coefficient of variation (CV) across HbA 1c measurements obtained from enrollment to the transition from intensive to standard glycemic therapy. Results During a median of 22,005, 23,121, and 13,080 person-years of follow-up, 2,905 nephropathy, 2,655 retinopathy, and 1,974 neuropathy cases were recorded, respectively. Median CV (IQR) was 7.91 % (5.66 %-10.76 %) in the standard treatment group and 9.79 % (7.32 %-13.35 %) in the intensive treatment group. In the standard treatment group, lower HbA 1c -CV (the first versus the second quartile) was associated with a higher risk of all microvascular outcomes, while higher HbA 1c -CV (the fourth quartile) was associated with a higher risk of nephropathy only. In the intensive treatment group, only higher HbA 1c -CV was associated with a higher risk of developing the microvascular outcomes. Intensive therapy reduced all microvascular outcomes among individuals with lower HbA 1c -CV, but increased the risk among those with the highest HbA 1c -CV (all P values for interaction < 0.0001). For example, hazard ratios (95 % CI) of retinopathy comparing intensive with standard treatments were 0.65 (0.56–0.75), 0.84 (0.71–0.98), 0.97 (0.82–1.14) and 1.28 (1.08–1.53) across the lowest to the highest quartiles of HbA 1c variability. Conclusions The effects of intensive glycemic control on microvascular outcomes in T2DM appear to be modified by the variability of HbA 1c during the treatment process, suggesting the significance of dynamic monitoring of HbA 1c levels and timely adjustments to the therapeutic strategy among individuals with a high HbA 1c variability.

Association of HbA1c with All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes

Prognostic Significance of Long-term HbA<sub>1c</sub> Variability for All-Cause Mortality in the ACCORD Trial

U-shaped association between HbA1c and all-cause mortality in CVD patients with diabetes

Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study

Association between glycated hemoglobin and risk of all‐cause mortality in community patients with type 2 diabetes: A prospective cohort study

Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study

Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes

Glycated Hemoglobin and All-Cause and Cause-Specific Mortality among Adults with and Without Diabetes.

Predictions of Diabetes Complications and Mortality Using Hba1c Variability: a 10-Year Observational Cohort Study

Prognostic Impact of HbA1c Variability on Long-Term Outcomes in Patients with Heart Failure and Type 2 Diabetes Mellitus

HbA1c and systolic blood pressure variation to predict all-cause mortality in patients with type 2 diabetes mellitus

Separate and Combined Effect of Visit-to-visit Glycaemic Variability and Mean Fasting Blood Glucose Level on All-Cause Mortality in Patients with Type 2 Diabetes: A Population-Based Cohort Study

Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular events

Relationship of Glycated Hemoglobin A1c with All-Cause and Cardiovascular Mortality among Patients with Hypertension

Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes

HbA1c Variability As an Independent Risk Factor for Microvascular Complications in Type 1 Diabetes

Glycemic Variability Modifies the Relationship Between Time in Range and Hemoglobin A1c Estimated from Continuous Glucose Monitoring: A Preliminary Study

Association of Visit-to-visit HbA1c Variability with Cardiovascular Diseases in Type 2 Diabetes Within or Outside the Target Range of HbA1c

Association Between Visit-to-visit HbA1c Variability and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes.

Effects of intensive glycemic control on microvascular outcomes in type 2 diabetes mellitus are modified by long-term HbA 1c variability: A post hoc analysis of the ACCORD trial

The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes